Cullgen to Absorb Pulmatrix, Join Nasdaq

Dow Jones2024-11-13

By Dean Seal

The biopharmaceutical company Cullgen intends to become a public company after agreeing to absorb the publicly traded Pulmatrix in a merger.

The Framingham, Mass.-based Pulmatrix said Wednesday that under the terms of the deal, its shareholders would own about 3.6% of the combined company and Cullgen stockholders would own the rest.

Pulmatrix shareholders are also set to receive a special cash dividend if the company's net cash at closing exceeds $2.5 million.

The combined company would be led by Cullgen Chairman and Chief Executive Ying Luo and Cullgen's board, with the addition of one representative of Pulmatrix. It would operate under the Cullgen name but trade on the Nasdaq Capital Market, where Pulmatrix is currently listed.

Pulmatrix said the combined company would have about $65 million in cash and cash equivalents, providing an expected runway through 2026.

The deal is expected to close by the end of March, subject to shareholder and regulatory approval.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

November 13, 2024 09:26 ET (14:26 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483889375?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-13 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483889375","market":"sg","top_or_hot":-1,"title":"Cullgen to Absorb Pulmatrix, Join Nasdaq","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n     By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  The biopharmaceutical company Cullgen intends to become a public company after agreeing to absorb the publicly traded Pulmatrix in a merger. \n</p>\n<p>\n  The Framingham, Mass.-based Pulmatrix said Wednesday that under the terms of the deal, its shareholders would own about 3.6% of the combined company and Cullgen stockholders would own the rest. \n</p>\n<p>\n  Pulmatrix shareholders are also set to receive a special cash dividend if the company's net cash at closing exceeds $2.5 million. \n</p>\n<p>\n  The combined company would be led by Cullgen Chairman and Chief Executive Ying Luo and Cullgen's board, with the addition of one representative of Pulmatrix. It would operate under the Cullgen name but trade on the Nasdaq Capital Market, where Pulmatrix is currently listed. \n</p>\n<p>\n  Pulmatrix said the combined company would have about $65 million in cash and cash equivalents, providing an expected runway through 2026. \n</p>\n<p>\n  The deal is expected to close by the end of March, subject to shareholder and regulatory approval. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2024 09:26 ET (14:26 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cullgen to Absorb Pulmatrix, Join Nasdaq</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCullgen to Absorb Pulmatrix, Join Nasdaq\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-13 22:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n     By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  The biopharmaceutical company Cullgen intends to become a public company after agreeing to absorb the publicly traded Pulmatrix in a merger. \n</p>\n<p>\n  The Framingham, Mass.-based Pulmatrix said Wednesday that under the terms of the deal, its shareholders would own about 3.6% of the combined company and Cullgen stockholders would own the rest. \n</p>\n<p>\n  Pulmatrix shareholders are also set to receive a special cash dividend if the company's net cash at closing exceeds $2.5 million. \n</p>\n<p>\n  The combined company would be led by Cullgen Chairman and Chief Executive Ying Luo and Cullgen's board, with the addition of one representative of Pulmatrix. It would operate under the Cullgen name but trade on the Nasdaq Capital Market, where Pulmatrix is currently listed. \n</p>\n<p>\n  Pulmatrix said the combined company would have about $65 million in cash and cash equivalents, providing an expected runway through 2026. \n</p>\n<p>\n  The deal is expected to close by the end of March, subject to shareholder and regulatory approval. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2024 09:26 ET (14:26 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2483889375","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483889375","pubTimestamp":1731507960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"The biopharmaceutical company Cullgen intends to become a public company after agreeing to absorb the publicly traded Pulmatrix in a merger.The Framingham, Mass.-based Pulmatrix said Wednesday that under the terms of the deal, its shareholders would own about 3.6% of the combined company and Cullgen stockholders would own the rest.Pulmatrix shareholders are also set to receive a special cash dividend if the company's net cash at closing exceeds $2.5 million.The combined company would be led by Cullgen Chairman and Chief Executive Ying Luo and Cullgen's board, with the addition of one representative of Pulmatrix. It would operate under the Cullgen name but trade on the Nasdaq Capital Market, where Pulmatrix is currently listed.Pulmatrix said the combined company would have about $65 million in cash and cash equivalents, providing an expected runway through 2026.The deal is expected to close by the end of March, subject to shareholder and regulatory approval.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","QID":"纳指两倍做空ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","TQQQ":"纳指三倍做多ETF","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","PULM":"Pulmatrix, Inc.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","QLD":"纳指两倍做多ETF","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","PSQ":"纳指反向ETF","BK4007":"制药",".IXIC":"NASDAQ Composite","SQQQ":"纳指三倍做空ETF"},"translate_title":"Cullgen将吸收Pulmatrix并加入纳斯达克","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":1,"MNQmain":0.6,"NQmain":1,"NDAQ":1,"PSQ":0.6,"PULM":1,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"By Dean Seal \n\n\n \n\n\n  The biopharmaceutical company Cullgen intends to become a public company after agreeing to absorb the publicly traded Pulmatrix in a merger. \n\n\n  The Framingham, Mass.-based Pulmatrix said Wednesday that under the terms of the deal, its shareholders would own about 3.6% of the combined company and Cullgen stockholders would own the rest. \n\n\n  Pulmatrix shareholders are also set to receive a special cash dividend if the company's net cash at closing exceeds $2.5 million. \n\n\n  The combined company would be led by Cullgen Chairman and Chief Executive Ying Luo and Cullgen's board, with the addition of one representative of Pulmatrix. It would operate under the Cullgen name but trade on the Nasdaq Capital Market, where Pulmatrix is currently listed. \n\n\n  Pulmatrix said the combined company would have about $65 million in cash and cash equivalents, providing an expected runway through 2026. \n\n\n  The deal is expected to close by the end of March, subject to shareholder and regulatory approval. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 09:26 ET (14:26 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483889375"}